Refractory very early-onset inflammatory bowel disease associated with cytosolic isoleucyl-tRNA synthetase deficiency: A case report.
Cytosolic isoleucine tRNA synthase
Gene
Hepatitis
Inflammatory bowel disease
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
21 Apr 2020
21 Apr 2020
Historique:
received:
06
01
2020
revised:
26
03
2020
accepted:
01
04
2020
entrez:
1
5
2020
pubmed:
1
5
2020
medline:
9
2
2021
Statut:
ppublish
Résumé
Aminoacyl tRNA synthetases/ligases (ARSs) are highly conserved enzymes involved in attaching amino acids to tRNA promoting protein synthesis. Although deficiencies of ARSs localized to the mitochondria classically present with neuropathology, the clinical features of cytosolic ARS deficiencies are more variable. They have previously been associated with neonatal hepatitis, but never with early-onset inflammatory bowel disease. A nine-year-old Bangladeshi boy presented with neonatal liver failure and deranged clotting, transaminitis and cholestasis. His parents were first cousins. Two older brothers and a sister were well. The patient suffered from loose stools from early infancy which became more troublesome and persistent from five years old with ten bloody motions a day. Repeated endoscopies showed persistent pancolitis, which was refractory to mesalazine, corticosteroids, azathioprine, sirolimus and anti-TNF (adalimumab) therapy, but has improved recently with subcutaneous methotrexate.Whole Genome Sequencing revealed a novel pathogenic missense variant (c.290A > G) in the cytosolic isoleucyl-tRNA synthetase gene, leading to an amino acid substitution (p.Asp97Gly). Pathogenic variants in other genes associated with inflammatory bowel disease (IBD) ( This case report provides evidence that recessive mutations in cytosolic isoleucyl-tRNA synthetase are a novel monogenic cause of IBD, which should be considered, particularly in infants and children with a history of neonatal hepatitis and very early-onset IBD poorly responsive to treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Aminoacyl tRNA synthetases/ligases (ARSs) are highly conserved enzymes involved in attaching amino acids to tRNA promoting protein synthesis. Although deficiencies of ARSs localized to the mitochondria classically present with neuropathology, the clinical features of cytosolic ARS deficiencies are more variable. They have previously been associated with neonatal hepatitis, but never with early-onset inflammatory bowel disease.
CASE SUMMARY
METHODS
A nine-year-old Bangladeshi boy presented with neonatal liver failure and deranged clotting, transaminitis and cholestasis. His parents were first cousins. Two older brothers and a sister were well. The patient suffered from loose stools from early infancy which became more troublesome and persistent from five years old with ten bloody motions a day. Repeated endoscopies showed persistent pancolitis, which was refractory to mesalazine, corticosteroids, azathioprine, sirolimus and anti-TNF (adalimumab) therapy, but has improved recently with subcutaneous methotrexate.Whole Genome Sequencing revealed a novel pathogenic missense variant (c.290A > G) in the cytosolic isoleucyl-tRNA synthetase gene, leading to an amino acid substitution (p.Asp97Gly). Pathogenic variants in other genes associated with inflammatory bowel disease (IBD) (
CONCLUSION
CONCLUSIONS
This case report provides evidence that recessive mutations in cytosolic isoleucyl-tRNA synthetase are a novel monogenic cause of IBD, which should be considered, particularly in infants and children with a history of neonatal hepatitis and very early-onset IBD poorly responsive to treatment.
Identifiants
pubmed: 32351297
doi: 10.3748/wjg.v26.i15.1841
pmc: PMC7183863
doi:
Substances chimiques
Isoleucine-tRNA Ligase
EC 6.1.1.5
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1841-1846Informations de copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors have declared no conflicts of interest.
Références
Am J Hum Genet. 2016 Aug 4;99(2):414-22
pubmed: 27426735
Genet Med. 2019 Feb;21(2):319-330
pubmed: 29875423
Mol Genet Metab. 2012 Jul;106(3):351-8
pubmed: 22607940
Hum Mutat. 2014 Nov;35(11):1285-9
pubmed: 25130867
Clin Immunol. 2012 Jun;143(3):207-9
pubmed: 22542741
Clin Genet. 2017 Jun;91(6):913-917
pubmed: 27891590
Biochem Biophys Res Commun. 2018 Oct 28;505(2):378-384
pubmed: 30262142
Clin Immunol. 2012 Jun;143(3):256-65
pubmed: 22472603
Clin Genet. 2017 Dec;92(6):671-673
pubmed: 29052218
Nat Commun. 2014 Nov 27;5:5650
pubmed: 25427601